2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole
A review of taints and odors in the pharmaceutical and consumer healthcare industries.


Pharmaceutical Technology
Volume 36, Issue 9, pp. 56-62

References

1. PDA, "Technical Report No. 55: Detection and Mitigation of 2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole Taints and Odors in the Pharmaceutical and Consumer Healthcare Industries," (April 2012), available at http://store.pda.org/ProductCatalog/Product.aspx?ID=1549.

2. Anon, "Organohalogen Taints in Foods," Australian Food and Grocery Council Supplement to Food Australia, 59 (3), (2007), http://www.afgc.org.au/cmsDocuments/Organohalogen.pdf

3. PDA, "Risk Mitigation of Tribromoanisole (TBA)/Trichloroanisole (TCA) Taints and Odors: A Pharmaceutical Industry Benchmarking Survey" (2011), available at http://store.pda.org/bookstore/ProductDetails.aspx?productabbreviation=45000.

4. FDA, "Questions and Answers on Current Good Manufacturing Practices, Good Guidance Practices, Level 2 Guidance–Buildings and Facilities" (FDA, Rockville, MD), http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm192869.htm.

5. T. Ramstad and J.S.Walker, Analyst 117 (8), 1361–1366 (1992).

6. R.J. Bleiler, F. Kuhrt, and D. Wright, Analytical Technology and Laboratory Testing, supp. to Pharm. Technol. 35 (11) s10-14 (2011).

7. F. Koshier et al., Food Chem. Toxicol. 49 (9), 2074–2080 (2011).

8. ICH, Q9 Quality Risk Management (2005).

9. ISO 13299:2003, Sensory Analysis-General Guidance for the Design of Test Rooms.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here